Navigation Links
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Date:3/30/2012

(2%).

Please visit www.DIFICID.com or call 855-DIFICID (343-4243) for full prescribing information for DIFICID.

About CDAD
Clostridium difficile-associated diarrhea (CDAD) has become a significant medical problem in hospitals, long-term care facilities and in the community. CDAD is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing C. difficile bacteria to flourish. Older patients in particular are at risk for CDAD, potentially because of a weakened immune system or the presence of underlying disease. Approximately two-thirds of CDAD patients are 65 years of age or older. Historically, approximately 20% to 30% of CDAD patients who initially respond to treatment experience a clinical recurrence.

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
3. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
4. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
5. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
8. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
9. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
10. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
11. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... According to a new ... type (SFE, Cold Pressed, Organic Solvent, & Others), and ... Fragrance, & Others) - Global Trends & Forecast ... the Amaranth Seed Oil Market with an analysis ... of value. The Amaranth Seed Oil Market size ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... Aug. 10, 2011 GNS Healthcare, Inc., (GNS) ... personalized medicine to improve human health, today announced ... Bristol-Myers Squibb Company (NYSE: BMY ) ... and biomarkers in the area of immuno-inflammation.  Utilizing ...
... Ardea Biosciences, Inc. (Nasdaq: RDEA ) announced today ... will present at the Wedbush Securities 2011 Life Sciences Management ... on Tuesday, August 16, 2011. This presentation ... Relations section of Ardea,s website at www.ardeabio.com . Please ...
Cached Medicine Technology:GNS Healthcare Announces Collaboration With Bristol-Myers Squibb 2Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference 2
(Date:8/29/2014)... of clinical trials based on administering antidepressants for ... that more trials are needed to determine whether ... on a regular basis., Dr. Ian Gilron, a ... the Department of Anesthesiology, and his team of ... the use of antidepressants for pain relief post-surgery ...
(Date:8/29/2014)... 2, 2014) A team of scientists from the ... breakthrough discovery of a process to expand production of ... could have implications that extend beyond cancer, including treatments ... In an article published Aug. 29 in ... Gates Center for Regenerative Medicine and Stem Cell Biology ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... new study from the research group of Dr. John Lewis ... Health Research Institute (London, ON) has confirmed that "invadopodia" play ... published in Cell Reports , shows preventing these tentacle-like ... , Roughly 2 in 5 Canadians will develop cancer ... die of the disease. In 2014, it,s estimated that nine ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Top10inaction, a ... web conference providers in the online service industry for ... were global leaders Webex, GotoMeeting and Infinite. , With ... users have to determine which provider is ideally a ... conference businesses search for compelling consumer goods and services ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... of Medicine (BUSM), Management (SMG) and Law (LAW), along ... that public-sector research has had a more immediate effect ... findings, which appear as a Special Article in the ... of Medicine , have economic and policy implications. ...
... HealthDay Reporter , WEDNESDAY, Feb. 9 (HealthDay ... cell genome revealed never-before-seen changes in DNA that may ... mapping the full genetic blueprint of the tumor, researchers ... of more targeted drugs and a better understanding of ...
... investing in public parks and recreation sites may be ... healthcare system, according to Penn State researchers. Investments in ... health and fitness, say Geof Godbey, professor emeritus of ... and parks management. "There is a strong relationship between ...
... heart disease, cancers, HIV and other diseases quickly and ... microsponges are an essential component of Rice University,s Programmable ... in the journal Small . The ... and Chemistry, and his colleagues at Rice,s BioScience Research ...
... Family Physicians demonstrates that vulvar cancer occurs most frequently in women ... with vulvar cancer are age 70 or older, and the rate ... by 75 years of age. , A team of researchers headed ... in Women,s Oncology at Women & Infants Hospital of Rhode Island, ...
... Poor memory and problems with other mental skills may be early ... Researchers gave a word recall memory test to 17,851 people, ... measure the brain,s executive functioning skills. The participants, who were aged ... stroke, were then contacted twice a year for up to 4.5 ...
Cached Medicine News:Health News:Researchers find public sector research responsible for many new drug discoveries 2Health News:Researchers find public sector research responsible for many new drug discoveries 3Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:Key to better health care may be a walk in the park 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:Researchers: Elderly patients 4 times more likely to die from treatment complications 2Health News:Could Poor Memory Signal Raised Stroke Risk? 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: